<DOC>
	<DOCNO>NCT02248168</DOCNO>
	<brief_summary>The objective study investigate issue question MIRAPEX Tablets show Post Marketing Surveillance ( PMS ) study upon approval . - Unexpected adverse event ( especially , serious adverse event ( SAEs ) ) - To find status incidence adverse event actual practice - Factors safety profile - Factors efficacy profile</brief_summary>
	<brief_title>Post Marketing Surveillance And Special Surveillance MirapexÂ® Tablet Patients With Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Among patient idiopathic Parkinson 's disease , receive MIRAPEX Tablets first contract study request number case consecutively enrol without skip Following patient contraindicate . 1 . Patients hypersensitive MIRAPEX ingredient 2 . Refer insert paper contraindication . Following patient carefully administer . 1 . Patient renal impairment 2 . Refer insert paper precaution .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>